Literature DB >> 25216089

Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine.

Fayna Diaz-San Segundo1, Camila C Dias2, Mauro P Moraes3, Marcelo Weiss2, Eva Perez-Martin2, Andres M Salazar4, Marvin J Grubman5, Teresa de Los Santos6.   

Abstract

Foot-and-mouth disease virus (FMDV) causes a highly contagious disease of cloven-hoofed animals. We have previously demonstrated that a replication-defective human adenovirus 5 vector carrying the FMDV capsid coding region of serotype A24 Cruzeiro (Ad5-CI-A24-2B) protects swine and cattle against FMDV challenge by 7 days post-vaccination. However, since relatively large amounts of Ad5-CI-A24-2B are required to induce protection this strategy could be costly for livestock production. Poly ICLC is a synthetic double stranded RNA that activates multiple innate and adaptive immune pathways. In this study, we have tested for the first time, the adjuvant effect of poly ICLC in combination with Ad5-CI-A24-2B in swine. We found that the combination resulted in a reduction of the vaccine protective dose by 80-fold. Interestingly, the lowest dose of Ad5-CI-A24-2B plus 1mg of poly ICLC protected animals against challenge even in the absence of detectable FMDV-specific neutralizing antibodies at the time of challenge. Published by Elsevier Inc.

Entities:  

Keywords:  Adjuvants; Cell-mediated immunity; Foot-and-mouth disease; Foot-and-mouth disease virus; Neutralizing antibodies; Poly ICLC; Replication-defective adenovirus; Vaccines

Mesh:

Substances:

Year:  2014        PMID: 25216089     DOI: 10.1016/j.virol.2014.08.012

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle.

Authors:  Gisselle N Medina; Nestor Montiel; Fayna Diaz-San Segundo; Diego Sturza; Elizabeth Ramirez-Medina; Marvin J Grubman; Teresa de los Santos
Journal:  Clin Vaccine Immunol       Date:  2015-11-25

2.  The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.

Authors:  Ekaterina Lebedeva; Alexander Bagaev; Alexey Pichugin; Marina Chulkina; Andrei Lysenko; Irina Tutykhina; Maxim Shmarov; Denis Logunov; Boris Naroditsky; Ravshan Ataullakhanov
Journal:  BMC Immunol       Date:  2018-07-28       Impact factor: 3.615

Review 3.  Biological Function and Application of Picornaviral 2B Protein: A New Target for Antiviral Drug Development.

Authors:  Zengbin Li; Zixiao Zou; Zeju Jiang; Xiaotian Huang; Qiong Liu
Journal:  Viruses       Date:  2019-06-04       Impact factor: 5.048

4.  Use of Synonymous Deoptimization to Derive Modified Live Attenuated Strains of Foot and Mouth Disease Virus.

Authors:  Fayna Diaz-San Segundo; Gisselle N Medina; Edward Spinard; Anna Kloc; Elizabeth Ramirez-Medina; Paul Azzinaro; Steffen Mueller; Elizabeth Rieder; Teresa de Los Santos
Journal:  Front Microbiol       Date:  2021-01-21       Impact factor: 5.640

Review 5.  Challenges of Generating and Maintaining Protective Vaccine-Induced Immune Responses for Foot-and-Mouth Disease Virus in Pigs.

Authors:  Nicholas A Lyons; Young S Lyoo; Donald P King; David J Paton
Journal:  Front Vet Sci       Date:  2016-11-30

6.  Low-dose oral interferon modulates expression of inflammatory and autoimmune genes in cattle.

Authors:  Stephen W Mamber; Jeremy Lins; Volkan Gurel; David P Hutcheson; Pablo Pinedo; David Bechtol; Steven Krakowka; Rachel Fields-Henderson; Joseph M Cummins
Journal:  Vet Immunol Immunopathol       Date:  2016-03-04       Impact factor: 2.046

7.  The antibody response induced FMDV vaccines in sheep correlates with early transcriptomic responses in blood.

Authors:  Bernard Klonjkowski; Isabelle Schwartz-Cornil; Luc Jouneau; David J Lefebvre; Fleur Costa; Aurore Romey; Sandra Blaise-Boisseau; Anthony Relmy; Yan Jaszczyszyn; Cloelia Dard-Dascot; Sébastien Déjean; Nicolas Versillé; Edouard Guitton; Pascal Hudelet; Marianne Curet; Kris De Clercq; Labib Bakkali-Kassimi; Stéphan Zientara
Journal:  NPJ Vaccines       Date:  2020-01-03       Impact factor: 7.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.